Project: Development of a first-in-class anti-CD36 biologic to treat metastatic cancer with high unmet need

Acronym	LIPOLOGIC (Reference Number: 114305)
Duration	01/10/2020 - 01/10/2022
Project Topic	The consortium will deliver a first-in-class biologic drug with a unique mode-of-action (MoA) for the treatment of metastatic cancer. The LIPOLOGIC drug blocks a novel target overexpressed on metastatic tumor cell (CD36) thereby inducing programmed cell-death of the metastatic cancer. This MoA has the potential to be applied to multiple metastatic cancers. By the end of the project, the lead candidate will be ready for IND/IMPD-enabling studies followed by a Phase I/II trial.
Network	Eurostars 2
Call	Eurostars Cut–off 13

Project partner

Number	Name	Role	Country
1	Absolute Antibody Ltd.	Partner	United Kingdom
2	ONA Therapeutics	Coordinator	Spain
3	Research Institute for Chromatography BVBA	Partner	Belgium